AARTIDRUGSNSEAarti Drugs Limited· PharmaceuticalsMediumNeutral
Announced Tue, 24 Mar · 18:17 IST

Aarti Drugs Limited has informed the Exchange about Credit Rating

Credit & Debt View source PDF

AARTIDRUGS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-2.2%1-day move
₹336.60
prior close
₹338.80
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+1.7+1.4+1.4+1.5-2.2-5.1+2.5+5.3+5.6+7.7+7.5+13.4+17.2+11.0
Up moveDown movePending
AI summary

ICRA Limited has reaffirmed the credit ratings on Aarti Drugs Limited's bank facilities totaling Rs. 1,452.80 crore. Long-term facilities — term loan of Rs. 253.13 crore, cash credit of Rs. 65 crore, and proposed term loan of Rs. 49.67 crore — retain [ICRA] AA- (Stable). Short-term fund and non-fund based facilities of Rs. 1,085 crore retain the highest [ICRA] A1+ rating. AA- is a high investment-grade rating, and A1+ is the top short-term grade, indicating strong financial health. The reaffirmation means the rating agency sees no change in the company's credit profile since its last review.

Likely market impact

Reaffirmation of high-grade ratings signals strong financial standing, easy access to bank credit, and stable borrowing costs — all positive for shareholders. No rating change means no immediate impact on the stock price from this announcement.